Skip to content
The markets have been showing mixed messages lately. A look at the chart shows that the NASDAQ’s rate of climb has been slowing recently, although it remains at record high levels. At the same time, the S&P 500 is holding just over 3,200, putting the index back within 5% of its all-time peak – but the Dow Jones appears to have hit a plateau. All of this raises some questions about the future of the market’s bull rally.Chief among those questions are worries about the resurgence of COVID-19 and the possibility of further lockdown policies. The state of California – which by itself is the world’s fifth largest economy, valued at over $2.6 trillion – has recently reimposed severe social distancing rules along with restrictions on businesses. Even Texas has imposed a mask mandate.Worried investors are looking for safety, which will naturally renew interest in dividend stocks. But not just any...
Mass demonstrations triggered by the arrest of a local governor in Russia's Far East have grown into a wave of dissatisfaction over social and economic struggles and the rule of Vladimir Putin, despite the president's recent referendum victory. Photo: Evgenii Pereverzev/Reuters...
In this article we are going to estimate the intrinsic value of Box, Inc. (NYSE:BOX) by projecting its future cash......
It’s far from business as usual at the Indianapolis headquarters of Eli Lilly, with only a sixth of the pharma company’s employees working on-site to develop potential Covid-19 treatments. WSJ’s Peter Loftus takes us inside. Photo: Eli Lilly...
BeiGene (BGNE) and Assembly Biosciences (ASMB) have announced a new collaboration in China for Assembly’s three clinical-stage core inhibitor candidates for the treatment of chronic hepatitis B virus (HBV) infection. Shares in ASMB are surging 9% in Monday’s pre-market trading, while BGNE is up 3%.Under the terms of the agreement, Assembly has granted BeiGene exclusive rights to develop and commercialize ABI-H0731, ABI-H2158 and ABI-H3733 in China, including Hong Kong, Macau, and Taiwan. ABI-H0731 and ABI-H2158 are in ongoing Phase 2 clinical trials and ABI-H3733 is in Phase 1 development.BeiGene will be responsible for development, regulatory submissions, and commercialization in China. Assembly retains full worldwide rights outside of the partnered territory for its HBV portfolio.Assembly will receive an upfront cash payment of $40 million plus up to $500 million in potential development, regulatory and net sales milestone payments. Assembly is also eligible to receive tiered royalties of net sales. BeiGene will contribute initial funding for clinical development in China, after...
(Bloomberg) -- Billionaire Jack Ma’s Ant Group is seeking a valuation north of $200 billion as it goes public in Hong Kong and Shanghai, people familiar with the matter said, kicking off a landmark coming-out party for China’s leader in internet finance.The parent of China’s largest mobile payment company will pursue a simultaneous dual-listing in Hong Kong and on the Shanghai stock exchange’s STAR board, the Hangzhou-based firm said, in what promises to be one of the largest debuts in years. Ant is already more richly valued than most Wall Street firms and, if conditions are favorable, it could seek to raise more in its IPOs than Saudi Aramco’s record $29 billion haul, one of the people said, asking not to be identified talking about a private deal.The crown jewel of the sprawling Alibaba empire, Ant has been accelerating its evolution into an online mall for everything from loans and travel...
